Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) EBITDA (2016 - 2025)

Creative Medical Technology Holdings has reported EBITDA over the past 16 years, most recently at -$1.9 million for Q4 2025.

  • Quarterly EBITDA fell 3.18% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.1 million through Dec 2025, down 6.95% year-over-year, with the annual reading at -$6.1 million for FY2025, 6.95% down from the prior year.
  • EBITDA was -$1.9 million for Q4 2025 at Creative Medical Technology Holdings, down from -$1.3 million in the prior quarter.
  • Over five years, EBITDA peaked at -$303944.0 in Q1 2021 and troughed at -$6.3 million in Q4 2022.
  • The 5-year median for EBITDA is -$1.3 million (2025), against an average of -$1.5 million.
  • Biggest five-year swings in EBITDA: tumbled 355.86% in 2021 and later surged 71.78% in 2023.
  • Tracing CELZ's EBITDA over 5 years: stood at -$1.5 million in 2021, then tumbled by 326.28% to -$6.3 million in 2022, then surged by 71.78% to -$1.8 million in 2023, then dropped by 6.43% to -$1.9 million in 2024, then dropped by 3.18% to -$1.9 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$1.9 million, -$1.3 million, and -$1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.